Arcellx, Inc.

Arcellx, Inc.ACLXEarnings & Financial Report

Nasdaq · Health Care · Biological Products, (No Diagnostic Substances)

Arcellx, Inc. is a clinical-stage biotechnology company that develops innovative chimeric antigen receptor T (CAR-T) cell therapies for treating hard-to-treat cancers including hematologic malignancies and solid tumors. Its core pipeline targets unmet oncology medical needs, serving global patient populations and partnering with life sciences stakeholders.

Top Holders

Holder% OwnedSharesChangeAs of
Gilead Sciences, Inc.12.90%
6.7M
2023-12-28
FMR LLC12.05%
6.5M
▲ +1.84pp2024-11-12
Paradigm BioCapital Advisors LP8.90%
4.8M
▲ +1.90pp2024-11-14
BlackRock, Inc.7.90%
4.2M
flat2024-11-08
New Enterprise Associates 15, L.P.7.80%
3.7M
2023-06-23
Perceptive Advisors LLC7.20%
3.9M
-1.60pp2024-11-14
NOS. OF ABOVE PERSONS5.20%
2.8M
▲ +0.20pp2024-11-22
Rami Elghandour5.00%
2.9M
2024-11-08
SR One Capital Management, LLC4.44%
2.3M
-2.02pp2024-03-25

Insider Transactions

Net 90d: $11.52M · buys $0 / sells $11.52M
Range:
Action:
Role:
InsiderRoleAction
2026-04-28Ali BehbahaniDirectorDisposed (U)
1.9K
2026-04-28Ali BehbahaniDirectorDisposed (U)
2.7K
2026-04-28Galligan Andrew HDirectorDisposed (U)
5.0K
2026-04-28Lubner David CharlesDirectorDisposed (U)
21.7K
2026-04-28Jill CarrollDirectorDisposed (U)
1.48M
2026-04-28Rami ElghandourSEE REMARKSDisposed (U)
174.9K
2026-04-28Rami ElghandourSEE REMARKSDisposed (U)
198.0K
2026-04-28Rami ElghandourSEE REMARKSDisposed (U)
218.5K
2026-04-28Rami ElghandourSEE REMARKSDisposed (U)
101.2K
2026-04-28Christopher HeeryCHIEF MEDICAL OFFICERDisposed (U)
23.7K
110 of 18
Page 1 / 2